転移性大腸癌市場の評価：治療タイプ・診断・エンドユーザー・地域別の機会および予測 (2017～2031年)

世界の転移性大腸癌の市場規模は、2023年の39億1,000万米ドルから、2024年から2031年の予測期間中は3.58%のCAGRで推移し、2031年には51億8,000万米ドルの規模に成長すると予測されています。

野菜や果物の摂取不足、アルコールの過剰摂取、座りがちな生活、喫煙、肥満、加工肉の多量摂取などによる大腸癌の有病率の増加が同市場に有利な成長機会をもたらしています。

転移性大腸癌市場の発展は、医療分野への支出増加、世界各国政府からの支援の強化、R&D活動の活発化、新規診断技術の開発や既存技術の強化に向けた取り組みの活発化など、さまざまな要因によって推進されています。認知度の向上、高齢化、手頃な価格の治療・診断ソリューションを提供するための政府のイニシアティブの高まりに加え、有利な償還政策も市場に有利な成長機会をもたらしています。

また、食品医薬品局 (FDA) を含むさまざまな規制機関による各種診断・治療ソリューションの承認の増加も市場の拡大をさらに後押ししています。例えば、2023年には、Foundation MedicineのFoundationOne Liquid CDxが、エンコラフェニブとセツキシマブの併用療法のコンパニオン診断薬としてFDAに承認されました。この併用療法は、BRAF V600E改変を伴う治療歴のある転移性大腸癌患者を対象にFDAの承認を受けました。

新規診断ソリューション開発のための研究活動が市場開拓を支える

転移性大腸癌は致死率が高いため、患者の予後を改善するためには早期発見が不可欠であり、大腸癌の転移性バイオマーカーのスクリーニングを目的としたさまざまな研究活動が行われています。例えば、イランのHamadan University of Medical Sciencesの研究者らは、実験的検証と機械学習アプローチを用いて、転移性大腸癌関連のバイオマーカーを研究しています。この研究結果は、機械学習アルゴリズムの助けを借りて、転移性大腸癌のバイオマーカーの同定に新たな知見を提供し、疾患治療のための革新的な治療戦略の基礎を築くことが期待されています。

戦略的提携が市場拡大をサポート

戦略的提携により、製薬会社は新薬を試験・開発し、必要な有効性と安全性の基準を満たし、医薬品開発プロセスを迅速に進めることができます。このような提携は医薬品の流通プロセスを強化し、医薬品の共同開発や商業化をサポートします。

当レポートでは、世界の転移性大腸癌の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の転移性大腸癌市場の展望

• 市場規模・予測
• 治療タイプ別
  • 化学療法
  • 手術
  • 標的療法
  • 放射線治療
  • 免疫療法
  • その他
• 診断別
  • 生検
  • 体外診断検査
  • 画像
  • その他
• エンドユーザー別
  • 病院
  • 癌研究機関
  • 外来診療センター
  • その他
• 地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ
• 企業別の市場シェア

第5章 世界の転移性大腸癌市場の展望：地域別

• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第6章 市場マッピング

• 治療タイプ別
• 診断別
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長阻害要因 (課題・抑制要因)

第9章 規制の枠組みとイノベーション

• 特許の情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (主要企業)
• 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Amgen, Inc.
• Sanofi S.A.
• F. Hoffmann-La Roche AG
• Eli Lilly and Company
• Bristol-Myers Squibb Co
• Bayer AG
• Merck & co., Inc.
• Abbott Laboratories
• Bruker Corporation
• Epigenomics AG

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1.Global Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 2.Global Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 3.Global Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 4.Global Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 5.Global Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 6.Global Metastatic Colorectal Cancer Market Share (%), By Region, 2017-2031F
• Figure 7.North America Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 8.North America Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 9.North America Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 10.North America Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 11.North America Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 12.North America Metastatic Colorectal Cancer Market Share (%), By Country, 2017-2031F
• Figure 13.United States Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 14.United States Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 15.United States Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 16.United States Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 17.United States Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 18.Canada Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 19.Canada Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 20.Canada Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 21.Canada Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 22.Canada Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 23.Mexico Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 24.Mexico Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 25.Mexico Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 26.Mexico Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 27.Mexico Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 28.Europe Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 29.Europe Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 30.Europe Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 31.Europe Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 32.Europe Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 33.Europe Metastatic Colorectal Cancer Market Share (%), By Country, 2017-2031F
• Figure 34.Germany Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 35.Germany Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 36.Germany Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 37.Germany Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 38.Germany Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 39.France Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 40.France Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 41.France Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 42.France Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 43.France Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 44.Italy Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 45.Italy Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 46.Italy Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 47.Italy Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 48.Italy Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 49.United Kingdom Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 50.United Kingdom Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 51.United Kingdom Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 52.United Kingdom Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 53.United Kingdom Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 54.Russia Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 55.Russia Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 56.Russia Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 57.Russia Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 58.Russia Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 59.Netherlands Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 60.Netherlands Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 61.Netherlands Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 62.Netherlands Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 63.Netherlands Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 64.Spain Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 65.Spain Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 66.Spain Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 67.Spain Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 68.Spain Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 69.Turkey Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 70.Turkey Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 71.Turkey Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 72.Turkey Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 73.Turkey Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 74.Poland Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 75.Poland Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 76.Poland Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 77.Poland Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 78.Poland Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 79.South America Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 80.South America Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 81.South America Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 82.South America Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 83.South America Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 84.South America Metastatic Colorectal Cancer Market Share (%), By Country, 2017-2031F
• Figure 85.Brazil Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 86.Brazil Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 87.Brazil Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 88.Brazil Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 89.Brazil Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 90.Argentina Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 91.Argentina Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 92.Argentina Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 93.Argentina Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 94.Argentina Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 95.Asia-Pacific Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 96.Asia-Pacific Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 97.Asia-Pacific Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 98.Asia-Pacific Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 99.Asia-Pacific Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 100.Asia-Pacific Metastatic Colorectal Cancer Market Share (%), By Country, 2017-2031F
• Figure 101.India Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 102.India Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 103.India Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 104.India Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 105.India Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 106.China Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 107.China Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 108.China Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 109.China Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 110.China Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 111.Japan Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 112.Japan Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 113.Japan Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 114.Japan Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 115.Japan Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 116.Australia Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 117.Australia Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 118.Australia Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 119.Australia Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 120.Australia Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 121.Vietnam Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 122.Vietnam Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 123.Vietnam Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 124.Vietnam Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 125.Vietnam Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 126.South Korea Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 127.South Korea Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 128.South Korea Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 129.South Korea Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 130.South Korea Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 131.Indonesia Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 132.Indonesia Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 133.Indonesia Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 134.Indonesia Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 135.Indonesia Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 136.Philippines Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 137.Philippines Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 138.Philippines Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 139.Philippines Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 140.Philippines Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 141.Middle East & Africa Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 142.Middle East & Africa Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 143.Middle East & Africa Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 144.Middle East & Africa Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 145.Middle East & Africa Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 146.Middle East & Africa Metastatic Colorectal Cancer Market Share (%), By Country, 2017-2031F
• Figure 147.Saudi Arabia Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 148.Saudi Arabia Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 149.Saudi Arabia Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 150.Saudi Arabia Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 151.Saudi Arabia Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 152.UAE Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 153.UAE Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 154.UAE Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 155.UAE Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 156.UAE Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 157.South Africa Metastatic Colorectal Cancer Market, By Value, in USD Billion, 2017-2031F
• Figure 158.South Africa Metastatic Colorectal Cancer Market, By Volume, in Million Units, 2017-2031F
• Figure 159.South Africa Metastatic Colorectal Cancer Market Share (%), By Treatment Type, 2017-2031F
• Figure 160.South Africa Metastatic Colorectal Cancer Market Share (%), By Diagnosis, 2017-2031F
• Figure 161.South Africa Metastatic Colorectal Cancer Market Share (%), By End-user, 2017-2031F
• Figure 162.By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 163.By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 164.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 165.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global metastatic colorectal cancer market is projected to witness a CAGR of 3.58% during the forecast period 2024-2031, growing from USD 3.91 billion in 2023 to USD 5.18 billion in 2031F. The increasing prevalence of colorectal cancer due to low intake of fruits and vegetables, excessive alcohol consumption, sedentary lifestyle, smoking, obesity, and high intake of processed meats is providing lucrative growth opportunities to the market.

Growth of the metastatic colorectal cancer market is driven by various factors including increased spendings towards healthcare sector, rising support from various governments across the globe, growing research and development activities, and rising efforts towards development of novel diagnostic techniques and enhancement of existing techniques. Increasing awareness, ageing population, and rising government initiatives to provide affordable treatment and diagnostic solutions in combination with the presence of favorable reimbursement policies providing lucrative growth opportunities to the market.

Increasing approval for various diagnostic and treatment solutions by different regulatory bodies including the Food and Drug Administration (FDA) is further supporting the market expansion. For instance, in 2023, the FDA approved Foundation Medicine's FoundationOne Liquid CDx as a companion diagnostic for encorafenib combined with cetuximab. The combination therapy received FDA approval for patients with previously treated metastatic colorectal cancer with BRAF V600E alteration.

FoundationOne Liquid CDx became the first comprehensive genomic profiling test that was approved by the Food and Drug Administration for detecting BRAF V600E mutations in patients with metastatic colorectal cancer. The companion diagnostic indication provides oncologists with non-invasive and important genomic testing solutions for patients with metastatic cancers.

Research Activities for Development of Novel Diagnostic Solutions Support Market Growth

Due to the high fatality rate of metastatic colorectal cancer, early detection is essential for enhancing patient outcomes therefore, various research activities are underway for screening metastatic biomarkers in colorectal cancer. For instance, research is being conducted by the researchers of Hamadan University of Medical Sciences, Hamadan, Iran for the investigation of metastatic colorectal cancer related biomarkers by employing experimental validation and a machine learning approach. The findings of the research are expected to offer novel insights for the identification of biomarkers for metastatic colorectal cancer with the help of machine learning algorithms, laying the groundwork for innovative therapeutic strategies for disease treatment. Through machine learning algorithms 11 biomarkers were identified and 4 were experimentally validated. The joint applications of these genes can augment the development of innovative AI predictive models and can be considered as a diagnostic panel for metastatic assessment.

Strategic Collaborations Support Market Expansion

Strategic collaborations allow pharmaceutical companies to test and develop novel drugs, ensuring that they meet the required efficacy and safety standards, and fast-track the drug development process. Such collaborations bolster the drug distribution process and support the co-development and commercialization of drugs. For instance, Taiho Pharmaceutical, the company that manufactures Lonsurf (trifluridine and tipiracil) signed an exclusive license agreement for commercializing and co-developing the drug with Servier in Europe. In August 2023, Lonsurf received approval from the Food and Drug Administration for treating patients with metastatic colorectal cancer in combination with bevacizumab or as a single agent in patients who were previously treated with anti-epidermal Growth Factor Receptor (EGFR) antibodies, fluoropyrimidine, bevacizumab, oxaliplatin, and irinotecan have been diagnosed with RAS wild-type metastatic colorectal cancer.

North America Accounts for Significant Market Share

It is estimated that colorectal cancer is the fourth most diagnosed cancer among individuals aging 30 to 39 years in the United States. The increasing prevalence of colorectal cancer, presence of a well-established healthcare infrastructure, and increasing investments by leading research institutions and market players towards metastatic colorectal cancer are supporting the market expansion in North America. The high awareness among the regional population about diagnostic devices and testing coupled with government policies is further supporting the market expansion in the region. The rising investments of various market players and research institutions towards research and development activities are providing lucrative growth opportunities to the market.

For instance, the University of Florida is conducting a randomized interventional phase 2 study to investigate the utilization of the standard scan-based approach versus the Signatera ctDNA assay for guiding treatment in patients suffering from metastatic colorectal cancer. The main aim of the study is to compare and measure the best overall response, survival, and progression-free survival of the subjects whose treatment had been developed using these two approaches.

Chemotherapy Holds a Significant Market Share

Utilization of chemotherapy for the treatment of metastatic colorectal cancer relieves symptoms and prolongs the lifespan of the patients. Chemotherapy is used for destroying cancer cells and preventing them from multiplying, dividing, and growing. It is a form of systemic medication that travels through the bloodstream, reaching all the body parts. Doublet chemotherapy or triplet therapy should be offered to patients suffering from initially unresectable and previously untreated metastatic colorectal cancer. Chemotherapy in combination with other therapies and surgeries is recommended for treatment of metastatic colorectal cancer.

For instance, anti-epidermal growth factor receptor therapy and chemotherapy is recommended for proficient mismatch repair left-sided treatment-naive RAS wild-type metastatic colorectal cancer and for proficient mismatch repair RAS wild-type right-sided metastatic colorectal cancer. System chemotherapy plus cytoreductive surgery is often recommended for selected patients, with colorectal peritoneal metastases. Surgery alone or perioperative chemotherapy are offered to patients with metastatic colorectal cancer who are candidates for curative resection of liver metastases.

Advancements in In-vitro Diagnostic Solutions

The continuous advancements in the development of diagnostic solutions are offering lucrative growth opportunities to the market. The advancements are ensuring the provision of quality care to patients suffering from metastatic colorectal cancer and garnering approval from different regulatory bodies. For instance, in 2023, the Food and Drug Administration approved a RAS Mutation Detection Kit as a companion diagnostic for panitum. The kit is expected to increase access to RAS testing at the mid and small-sized laboratories by improving the turnaround time and simplifying the testing procedure while lowering the diagnostic costs. The molecular in-vitro diagnostic tool has been designed for detecting thirty-five variants of KRAS and NRAS exon 2, 3, and 4 somatic mutations in patients suffering from colorectal cancer via the extracted genomic DNA from paraffin-embedded, formalin-fixed embedded colorectal cancer tissue samples.

Future Market Scenario (2024 - 2031F)

Drug delivery systems using bacteria, cell manipulation techniques for immunotherapy, and nanotechnology promise viable and emerging therapeutic options for patients who are not benefitting from the treatment options that are currently available. Combining nanotechnology with immunotherapy and other targeted therapies as a means of delivering drugs that have systemic toxicity and are otherwise non-selective is expected to offer novel strategic venue for the treatment of metastatic colorectal cancer. Emerging technologies in pre-clinical phase studies including immunostimulatory cytokines, microbial therapies, and nanotechnology offer possibilities for therapeutic deliveries.

Key Players Landscape and Outlook

Key participants in the metastatic colorectal cancer market are Amgen, Inc., Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Company, and Bristol-Myers Squibb Co. The market is expected to witness significant growth over the forecast period due to rising research and development activities by the leading market players.

In 2023, Amgen released data from their global Phase 3 CodeBreaK 300 trial that evaluated panitumumab in combination with two doses of sotorasib. The doses showed statistically significant superiority and the results were showcased during the European Society for Medical Oncology (ESMO) 2023. The data showed consistent efficacy across major subgroups and supports the combination of the two biomarker-directed therapies.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Metastatic Colorectal Cancer Market Outlook, 2017-2031F

• 4.1.Market Size & Forecast
  • 4.1.1.By Value
  • 4.1.2.By Volume
• 4.2.By Treatment type
  • 4.2.1.Chemotherapy
  • 4.2.2.Surgery
  • 4.2.3.Targeted Therapy
  • 4.2.4.Radiation Therapy
  • 4.2.5.Immunotherapy
  • 4.2.6.Others
• 4.3.By Diagnosis
  • 4.3.1.Biopsy
  • 4.3.2.In-vitro Diagnostic Testing
  • 4.3.3.Imaging
  • 4.3.4.Others
• 4.4.By End-user
  • 4.4.1.Hospitals
  • 4.4.2.Cancer Research Institutes
  • 4.4.3.Ambulatory Care Centers
  • 4.4.4.Others
• 4.5.By Region
  • 4.5.1.North America
  • 4.5.2.South America
  • 4.5.3.Europe
  • 4.5.4.Asia-Pacific
  • 4.5.5.Middle East & Africa
• 4.6.By Company Market Share (%), 2023

5.Global Metastatic Colorectal Cancer Market Outlook, By Region, 2017-2031F

• 5.1.North America*
  • 5.1.1.Market Size & Forecast
    • 5.1.1.1.By Value
    • 5.1.1.2.By Volume
  • 5.1.2.By Treatment Type
    • 5.1.2.1.Chemotherapy
    • 5.1.2.2.Surgery
    • 5.1.2.3.Targeted Therapy
    • 5.1.2.4.Radiation Therapy
    • 5.1.2.5.Immunotherapy
    • 5.1.2.6.Others
  • 5.1.3.By Diagnosis
    • 5.1.3.1.Biopsy
    • 5.1.3.2.In-vitro Diagnostic Testing
    • 5.1.3.3.Imaging
    • 5.1.3.4.Others
  • 5.1.4.By End-user
    • 5.1.4.1.Hospitals
    • 5.1.4.2.Cancer Research Institutes
    • 5.1.4.3.Ambulatory Care Centers
    • 5.1.4.4.Others
  • 5.1.5.United States*
    • 5.1.5.1.Market Size & Forecast
    • 5.1.5.1.1.By Value
    • 5.1.5.1.2.By Volume
    • 5.1.5.2.By Treatment Type
    • 5.1.5.2.1.Chemotherapy
    • 5.1.5.2.2.Surgery
    • 5.1.5.2.3.Targeted Therapy
    • 5.1.5.2.4.Radiation Therapy
    • 5.1.5.2.5.Immunotherapy
    • 5.1.5.2.6.Others
    • 5.1.5.3.By Diagnosis
    • 5.1.5.3.1.Biopsy
    • 5.1.5.3.2.In-vitro Diagnostic Testing
    • 5.1.5.3.3.Imaging
    • 5.1.5.3.4.Others
    • 5.1.5.4.By End-user
    • 5.1.5.4.1.Hospitals
    • 5.1.5.4.2.Cancer Research Institutes
    • 5.1.5.4.3.Ambulatory Care Centers
    • 5.1.5.4.4.Others
  • 5.1.6.Canada
  • 5.1.7.Mexico

All segments will be provided for all regions and countries covered

• 5.2.Europe
  • 5.2.1.Germany
  • 5.2.2.France
  • 5.2.3.Italy
  • 5.2.4.United Kingdom
  • 5.2.5.Russia
  • 5.2.6.Netherlands
  • 5.2.7.Spain
  • 5.2.8.Turkey
  • 5.2.9.Poland
• 5.3.Asia-Pacific
  • 5.3.1.India
  • 5.3.2.China
  • 5.3.3.Japan
  • 5.3.4.Australia
  • 5.3.5.Vietnam
  • 5.3.6.South Korea
  • 5.3.7.Indonesia
  • 5.3.8.Philippines
• 5.4.South America
  • 5.4.1.Brazil
  • 5.4.2.Argentina
• 5.5.Middle East & Africa
  • 5.5.1.Saudi Arabia
  • 5.5.2.UAE
  • 5.5.3.South Africa

6.Market Mapping, 2023

• 6.1.By Treatment Type
• 6.2.By Diagnosis
• 6.3.By End-user
• 6.4.By Region

7.Macro Environment and Industry Structure

• 7.1.Supply Demand Analysis
• 7.2.Import Export Analysis
• 7.3.Value Chain Analysis
• 7.4.PESTEL Analysis
  • 7.4.1.Political Factors
  • 7.4.2.Economic System
  • 7.4.3.Social Implications
  • 7.4.4.Technological Advancements
  • 7.4.5.Environmental Impacts
  • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5.Porter's Five Forces Analysis
  • 7.5.1.Supplier Power
  • 7.5.2.Buyer Power
  • 7.5.3.Substitution Threat
  • 7.5.4.Threat from New Entrant
  • 7.5.5.Competitive Rivalry

8.Market Dynamics

• 8.1.Growth Drivers
• 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

• 9.1.Patent Landscape
• 9.2.Regulatory Approvals
• 9.3.Innovations/Emerging Technologies

10.Key Players Landscape

• 10.1.Competition Matrix of Top Five Market Leaders
• 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4.SWOT Analysis (For Five Market Players)
• 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

• 13.1.Amgen, Inc.
  • 13.1.1.Company Details
  • 13.1.2.Key Management Personnel
  • 13.1.3.Products & Services
  • 13.1.4.Financials (As reported)
  • 13.1.5.Key Market Focus & Geographical Presence
  • 13.1.6.Recent Developments
• 13.2.Sanofi S.A.
• 13.3.F. Hoffmann-La Roche AG
• 13.4.Eli Lilly and Company
• 13.5.Bristol-Myers Squibb Co
• 13.6.Bayer AG
• 13.7.Merck & co., Inc.
• 13.8.Abbott Laboratories
• 13.9.Bruker Corporation
• 13.10.Epigenomics AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14.Strategic Recommendations

15.About Us & Disclaimer